1
|
Gomez-Rosas P, Pesenti M, Verzeroli C, Giaccherini C, Russo L, Sarmiento R, Masci G, Celio L, Minelli M, Gamba S, Tartari CJ, Tondini C, Giuliani F, Petrelli F, D'Alessio A, Gasparini G, Labianca R, Santoro A, De Braud F, Marchetti M, Falanga A. Validation of the Role of Thrombin Generation Potential by a Fully Automated System in the Identification of Breast Cancer Patients at High Risk of Disease Recurrence. TH OPEN 2021; 5:e56-e65. [PMID: 33585786 PMCID: PMC7875677 DOI: 10.1055/s-0040-1722609] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/23/2020] [Accepted: 12/07/2020] [Indexed: 01/11/2023] Open
Abstract
Background
The measurement of thrombin generation (TG) potential by the calibrated automated thrombogram (CAT) assay provides a strong contribution in identifying patients at high risk of early disease recurrence (E-DR). However, CAT assay still needs standardization and clinical validation.
Objective
In this study, we aimed to validate the role of TG for E-DR prediction by means of the fully automated ST Genesia system.
Methods
A prospective cohort of 522 patients from the HYPERCAN study with newly diagnosed resected high-risk breast cancer was included. Fifty-two healthy women acted as controls. Plasma samples were tested for protein C, free-protein S, and TG by ST Genesia by using the STG-ThromboScreen reagent with and without thrombomodulin (TM).
Results
In the absence of TM, patients showed significantly higher peak and ETP compared with controls. In the presence of TM, significantly lower inhibition of ETP and Peak were observed in patients compared with controls. E-DR occurred in 28 patients; these patients had significantly higher peak and endogenous thrombin potential (ETP) in the absence of TM compared with disease-free patients. Multivariable analysis identified mastectomy, luminal B HER2-neg, triple negative subtypes, and ETP as independent risk factors for E-DR. These variables were combined to generate a risk assessment score, able to stratify patients in three-risk categories. The E-DR rates were 0, 4.7, and 13.5% in the low-, intermediate-, and high-risk categories (hazard ratio = 8.7;
p
< 0.05, low vs. high risk).
Conclusion
Our data validate the ETP parameter with a fully automated standardized system and confirm its significant contribution in identifying high-risk early breast cancer at risk for E-DR during chemotherapy.
Collapse
Affiliation(s)
- Patricia Gomez-Rosas
- Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy.,Hematology Service, Hospital General Regional Tecamac, IMSS, Estado de Mexico, Mexico
| | - Marina Pesenti
- Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy
| | - Cristina Verzeroli
- Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy
| | - Cinzia Giaccherini
- Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy
| | - Laura Russo
- Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy
| | - Roberta Sarmiento
- Oncology Unit, Hospitals San Filippo Neri and San Giovanni Addolorata, Rome, Italy
| | - Giovanna Masci
- Medical Oncology and Hematology, IRCCS Humanitas Institute, Rozzano, Italy
| | - Luigi Celio
- Medical Oncology and Hematology, IRCCS National Cancer Institute, Milan, Italy
| | - Mauro Minelli
- Oncology Unit, Hospitals San Filippo Neri and San Giovanni Addolorata, Rome, Italy
| | - Sara Gamba
- Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy
| | - Carmen Julia Tartari
- Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy
| | - Carlo Tondini
- Oncology Unit, Hospital Papa Giovanni XXIII, Bergamo, Italy
| | - Francesco Giuliani
- Medical Oncology Unit, IRCCS Istituto Tumori Giovanni Paolo II, Bari, Italy
| | - Fausto Petrelli
- Oncology Unit, Hospital Treviglio-Caravaggio, Treviglio, Italy
| | - Andrea D'Alessio
- Department of Medicine, Gruppo San Donato, Policlinico San Marco, Bergamo, Italy
| | - Giampietro Gasparini
- Oncology Unit, Hospitals San Filippo Neri and San Giovanni Addolorata, Rome, Italy
| | - Roberto Labianca
- Department of Oncology Bergamo Province, Hospital Papa Giovanni XXIII, Bergamo, Italy
| | - Armando Santoro
- Medical Oncology and Hematology, IRCCS Humanitas Institute, Rozzano, Italy
| | - Filippo De Braud
- Medical Oncology and Hematology, IRCCS National Cancer Institute, Milan, Italy
| | - Marina Marchetti
- Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy
| | - Anna Falanga
- Immunohematology and Transfusion Medicine, Hospital Papa Giovanni XXIII, Bergamo, Italy.,School of Medicine, University of Milan Bicocca, Italy
| | | |
Collapse
|
2
|
Andresen MS, Stavik B, Sletten M, Tinholt M, Sandset PM, Iversen N, Skretting G. Indirect regulation of TFPI-2 expression by miR-494 in breast cancer cells. Sci Rep 2020; 10:4036. [PMID: 32132611 PMCID: PMC7055239 DOI: 10.1038/s41598-020-61018-x] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/19/2019] [Accepted: 02/18/2020] [Indexed: 01/01/2023] Open
Abstract
TFPI-2 has been shown to be involved in breast cancer pathogenesis by inhibiting extracellular matrix degradation, and low levels are associated with disease progression. As microRNA-494 (miR-494) protects against breast cancer progression, we investigated whether miR-494 is involved in the regulation of TFPI-2 in MCF-7 breast cancer cells. TFPI-2 mRNA and protein levels increased after transfection with miR-494 mimic, and TFPI-2 mRNA and miR-494 levels correlated positively in tumors from breast cancer patients. No specific binding sites for miR-494 in the 3'-untranslated region (UTR) of TFPI2 were identified; however, miR-494 was predicted in silico to bind 3'-UTR of the transcription factors AHR and ELF-1, which have potential binding sites in the TFPI2 promoter. ELF-1 mRNA was downregulated whereas AHR mRNA levels were upregulated after transfection with miR-494 mimic. Knockdown of ELF-1 and AHR increased and reduced TFPI-2 mRNA levels, respectively. Increased luciferase activity was seen when TFPI-2 promoter constructs containing the potential AHR or ELF-1 binding sites were co-transfected with miR-494 mimic. In conclusion, TFPI-2 mRNA levels were upregulated by miR-494 in MCF-7 breast cancer cells most likely by an indirect association where miR-494 targeted the transcription factors AHR and ELF-1. This association was supported in a breast cancer cohort.
Collapse
Affiliation(s)
- Marianne S Andresen
- Department of Haematology, Oslo University Hospital, Box 4950 Nydalen, 0424, Oslo, Norway. .,Research Institute of Internal Medicine, Oslo University Hospital, Box 4950 Nydalen, 0424, Oslo, Norway.
| | - Benedicte Stavik
- Department of Haematology, Oslo University Hospital, Box 4950 Nydalen, 0424, Oslo, Norway.,Research Institute of Internal Medicine, Oslo University Hospital, Box 4950 Nydalen, 0424, Oslo, Norway
| | - Marit Sletten
- Department of Medical Genetics, Oslo University Hospital, Box 4950 Nydalen, 0424, Oslo, Norway
| | - Mari Tinholt
- Department of Haematology, Oslo University Hospital, Box 4950 Nydalen, 0424, Oslo, Norway.,Department of Medical Genetics, Oslo University Hospital, Box 4950 Nydalen, 0424, Oslo, Norway
| | - Per Morten Sandset
- Department of Haematology, Oslo University Hospital, Box 4950 Nydalen, 0424, Oslo, Norway.,Research Institute of Internal Medicine, Oslo University Hospital, Box 4950 Nydalen, 0424, Oslo, Norway.,Institute of Clinical Medicine, University of Oslo, Box 1072 Blindern, 0316, Oslo, Norway
| | - Nina Iversen
- Department of Medical Genetics, Oslo University Hospital, Box 4950 Nydalen, 0424, Oslo, Norway
| | - Grethe Skretting
- Department of Haematology, Oslo University Hospital, Box 4950 Nydalen, 0424, Oslo, Norway.,Research Institute of Internal Medicine, Oslo University Hospital, Box 4950 Nydalen, 0424, Oslo, Norway
| |
Collapse
|
3
|
Tinholt M, Garred Ø, Borgen E, Beraki E, Schlichting E, Kristensen V, Sahlberg KK, Iversen N. Subtype-specific clinical and prognostic relevance of tumor-expressed F5 and regulatory F5 variants in breast cancer: the CoCaV study. J Thromb Haemost 2018; 16:1347-1356. [PMID: 29766637 DOI: 10.1111/jth.14151] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2018] [Indexed: 02/05/2023]
Abstract
Essentials The role of coagulation factor V (encoded by F5) in cancer pathogenesis is unknown. The clinical significance of tumor-expressed F5 was evaluated in breast cancer patient cohorts. F5 was expressed in human breast tumors, and the expression was higher than in normal tissue. High F5 expression was associated with aggressive tumors, but also with survival in breast cancer. SUMMARY Background Tumor expression of certain coagulation factors has been linked to cancer progression. Single nucleotide polymorphisms (SNPs) in F5 (encoding the FV protein) have been found to be associated with breast cancer; however, the role of coagulation factor V (FV) in cancer pathogenesis remains undiscovered. Objectives We aimed to investigate the clinical significance of FV and the regulatory role of F5 gene variants in breast cancer. Patients/Methods A Scandinavian 503-sample breast cancer cohort and three public breast cancer datasets (GOBO, TCGA and KM plotter) were used to determine associations between F5 gene expression (tumor-specific), circulating FV, F5 SNPs, clinical characteristics and breast cancer survival. Immunohistochemistry (IHC) was used to detect FV antigen in tumors. Results F5 expression was 2-fold higher in breast tumors compared with normal tissue, and the presence of FV antigen in breast tumors was confirmed by IHC staining. F5 expression was increased in patients with hormone receptor negative tumors, triple negative tumors, HER2-enriched and basal-like tumors. In patients with basal tumors, high expression of F5 was associated with improved overall survival (hazard ratio, HR = 0.52, 95% confidence interval, 0.31-0.86). SNPs in F5 were associated with tumor size and luminal A tumors. The rs6427202-rs9332542 C-G haplotype, previously associated with breast cancer, displayed a cis-regulatory effect on F5 expression in tumors and plasma FV antigen levels. In silico mining supported this regulatory function. Conclusions FV was a possible marker of aggressive breast cancer, yet also a predictor of favorable outcome. Evaluation of FV expression may be clinically useful for prognosis and treatment decisions in aggressive breast cancer.
Collapse
Affiliation(s)
- M Tinholt
- Department of Medical Genetics, Oslo University Hospital, Oslo, Norway
- Department of Haematology, Oslo University Hospital, Oslo, Norway
| | - Ø Garred
- Department of Pathology, Oslo University Hospital, Oslo, Norway
| | - E Borgen
- Department of Pathology, Oslo University Hospital, Oslo, Norway
| | - E Beraki
- Department of Pathology, Oslo University Hospital, Oslo, Norway
| | - E Schlichting
- Department of Breast and Endocrine Surgery, Oslo University Hospital, Oslo, Norway
| | - V Kristensen
- Department of Genetics, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, Oslo, Norway
- Department of Clinical Molecular Biology (EpiGen), Akershus University Hospital, Lørenskog, Norway
| | - K K Sahlberg
- Department of Genetics, Institute for Cancer Research, Oslo University Hospital, Radiumhospitalet, Oslo, Norway
- Department of Research, Vestre Viken, Drammen, Norway
| | - N Iversen
- Department of Medical Genetics, Oslo University Hospital, Oslo, Norway
| |
Collapse
|
4
|
The effect of Diosmin on the blood proteome in a rat model of venous thrombosis. Int J Biol Macromol 2017; 104:778-787. [PMID: 28606843 DOI: 10.1016/j.ijbiomac.2017.06.045] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2017] [Revised: 05/31/2017] [Accepted: 06/07/2017] [Indexed: 12/20/2022]
Abstract
Diosmin is the aglycone moiety of diosmetin (3',5,7 trihydroxy-4'methoxy radicals flavonoids), a naturally occurring flavone glycoside, whose antithrombotic effect was studied in rats. This study was designed to find the protein changes of venous thrombosis in Wistar rats comparing conditions with and without Diosmin treatment by two-dimensional gel electrophoresis (2-DE), and investigate the effect of a crucial protein known as CEP350 on human vascular endothelial cell growth. Through prior chromatographic purification with macroporous absorption resin (AB-8) and polyamide, Diosmin was isolated from Galium verum L. by solvent extraction, then purified to 98% purity using HPLC. Wistar rats were divided into control group, model group, and prevention group. And their venous thrombosis tissue segments were dissected and prepared for histopathological examination and detection of plasma protein C (PC). Next, proteomic analysis was performed with the samples. Low-abundance proteins of the three groups were separated by two-dimensional gel electrophoresis (2-DE). 2-DE analysis revealed that 191 protein spots were differentially expressed among those three groups. For protein identification, we selected six spots to use matrix assisted laser desorption/ionization-time of flight-mass spectrometry (MALDI-TOF-MS) detection, and then do the homology search in NCBI database. Considering characteristics of these proteins, we proposed CEP350 is related to spindle assembly. Furthermore, we used Lipofectamine 2000 to transfect HUVECs with CEP350 siRNA and evaluated the extent of silencing using real time-polymerase chain reaction (RT-PCR). Cells were stained for immunofluorescence with tubulin-tracker red, and structural changes were analyzed using laser scanning confocal microscope. We concluded that CEP350 depletion decreased microtubule stability. Dosmin could modulate the assemble of spindle from unevenly distributing and protect body from varicose veins by regulating CEP350.
Collapse
|
5
|
Yang X, Ren H, Sun Y, Zhang L, Yang X, Li H, Shao Y, Fu J. The prognostic value of D-dimer levels in endometrial cancer patients treated with intensity-modulated radiation therapy. Oncotarget 2017; 8:25279-25288. [PMID: 28445972 PMCID: PMC5421929 DOI: 10.18632/oncotarget.15805] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2016] [Accepted: 02/08/2017] [Indexed: 11/25/2022] Open
Abstract
Explain the important role of plasma D-dimer in cancers. Plasma D-dimer is increased in various tumors. However, the predictive value of plasma D-dimer is unclear. This study is aimed to evaluate the prognostic value of the D-dimer level in patients managed with intensity-modulated radiation for endometrial cancer. The D-dimer levels of forty patients with endometrial cancer were assessed before (D1) and after (D2) intensity-modulated radiation therapy (IMRT), respectively. The D-dimer level changes (ΔD) were defined as D2 minus D1. Cox regression and log-rank tests were used to evaluate the D-dimer levels in relation to progression free survival (PFS) and overall survival (OS). The OS and PFS of patients with a low D1 were significantly longer than those with a high D1 (P< 0.001, P< 0.001). We saw the similar correlation between D2, PFS and OS (P< 0.001, P< 0.001). Multivariate survival analyses showed that D-dimer was independently associated with OS and PFS in patients with endometrial cancer. The ΔD level was not related to the OS and PFS in endometrial cancer patients. The levels of D-dimer may be considered as an important predictor of PFS and OS in endometrial cancer patients treated with IMRT.
Collapse
Affiliation(s)
- Xiaojing Yang
- Department of Radiation Oncology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China
| | - Hanru Ren
- Department of Orthopaedics, Shanghai Pudong Hospital, Fudan University, Pudong Medical Center, Shanghai, China
| | - Yi Sun
- Department of Radiation Oncology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China
| | - Lihua Zhang
- Department of Radiation Oncology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China
| | - Xinmiao Yang
- Department of Radiation Oncology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China
| | - Hongling Li
- Department of Radiation Oncology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China
| | - Yuhui Shao
- Department of Radiation Oncology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China
| | - Jie Fu
- Department of Radiation Oncology, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China
| |
Collapse
|